Liquid biopsy could identify cancer patients at risk of metastatic disease, offering an opportunity to tailor treatment
Researchers at The Royal Marsden say ctDNA, a form of liquid biopsy, may be an accurate technique to monitor treatment response in patients with locally advanced rectal cancer, allowing treatment to be adapted or changed earlier to try to prevent the development of metastatic disease. Results from the study, led by researchers at The Royal